

MISSISSIPPI DIVISION OF MEDICAID

Pharmacy & Therapeutics Committee

Table 100 / Flowood, MS

August 13, 2024

10:00am to 2:00pm

AGENDA

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of May 14, 2024 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Public Comment
- VII. New Drug/New Generic Reviews
 1. **Anticonvulsants (Selected Benzodiazepines):** Libervant (diazepam) – *Financial Review Only*
 2. **Antineoplastics – Selected Systemic Enzyme Inhibitors:** Ojemda (tovorafenib)
 3. **Cytokine & Cam Antagonists:** Rinvoq LQ (upadacitinib) – *Financial Review Only*, Simlandi (adalimumab-ryvk) – *Financial Review Only*, Tofidence (tocilizumab-bavi) – *Financial Review Only*, Tyenee (tocilizumab-aazg) – *Financial Review Only*
 4. **Factor Deficiency Products (Factor IX):** Beqvez (fidanacogene elaparovecdzkt)
 5. **Immunosuppressive (Oral):** Myhibbin (mycophenolate mofetil) – *Financial Review Only*
 6. **Movement Disorder Agents:** Ingrezza Sprinkle Cap (valbenazine) – *Financial Review Only*
 7. **Opiate Dependence Treatments (Treatment):** Rextovy (naloxone) – *Financial Review Only*
 8. **Pulmonary Antihypertensives (Activin Signaling Inhibitor):** Winrevair (sotatercept-csrk)
 9. **Pulmonary Antihypertensives (Combination Agents):** Opsyntvi (macitentan/tadalafil)
- VIII. Other Business
- IX. Division of Medicaid Update
- X. Remaining 2024 Meeting Dates
 1. Tuesday, October 22, 2024